This is a routine board departure with no trading implications. Monitor for any future board composition changes or patterns, but no action is warranted based on this filing alone.
ABEO drugs
ABEO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 12 $5.53entry
- T+1 · 5mo ago +2.53%α +0.77% · $5.67
- T+5 · 5mo ago +4.34%α +3.67% · $5.77
- T+20 · 4mo ago +26.22%α +24.44% · $6.98
- T+60 · due 2mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Board member Michael Amoroso resigned from Abeona Therapeutics' Board of Directors and its Nominating and Corporate Governance Committee effective June 11, 2026, citing personal reasons. The filing explicitly states the resignation was not due to any disagreement with the company. This is a routine director departure with no operational or financial impact.
Key Facts
- Michael Amoroso resigned from the Board of Directors effective June 11, 2026
- Resignation also covered his role on the Nominating and Corporate Governance Committee
- Resignation was for personal reasons, not due to any disagreement with the company
- No replacement was named in the filing
- No other officers or directors were impacted
Financial Impact
No financial impact
Risk Factors
- Potential governance concerns if multiple board departures occur in a short period, though none indicated here
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-028369 |
| Document: 0001493152-26-028369-index-headers.html | 0001493152-26-028369 |
| Document: 0001493152-26-028369-index.html | 0001493152-26-028369 |
| Document: 0001493152-26-028369.txt | 0001493152-26-028369 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers